{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:37:13Z","timestamp":1790883433734,"version":"4.1.0"},"reference-count":31,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["Clinical Research Scholars Program"],"award-info":[{"award-number":["Clinical Research Scholars Program"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["EnVision CF: Emerging Leaders in CF Endocrinology"],"award-info":[{"award-number":["EnVision CF: Emerging Leaders in CF Endocrinology"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["Harry Shwachman Clinical Investigator Award"],"award-info":[{"award-number":["Harry Shwachman Clinical Investigator Award"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1R01DK119699-01"],"award-info":[{"award-number":["1R01DK119699-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32DK007028"],"award-info":[{"award-number":["T32DK007028"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Cystic fibrosis\u2013related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis and adds significant morbidity and treatment burden. We evaluated the safety and efficacy of automated insulin delivery with the iLet bionic pancreas (BP) in adults with CFRD in a single-center, open-label, random-order, crossover trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Twenty participants with CFRD were assigned in random order to 14 days each on the BP or their usual care (UC). No restrictions were placed on diet or activity. The primary outcome was the percent time sensor-measured glucose was in target range 70\u2013180 mg\/dL (time in range [TIR]) on days 3\u201314 of each arm, and key secondary outcomes included mean continuous glucose monitoring (CGM) glucose and the percent time sensor-measured glucose was in hypoglycemic range &amp;lt;54 mg\/dL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>TIR was significantly higher in the BP arm than the UC arm (75 \u00b1 11% vs. 62 \u00b1 22%, P = 0.001). Mean CGM glucose was lower in the BP arm than in the UC arm (150 \u00b1 19 vs. 171 \u00b1 45 mg\/dL, P = 0.007). There was no significant difference in percent time with sensor-measured glucose &amp;lt;54 mg\/dL (0.27% vs. 0.36%, P = 1.0), although self-reported symptomatic hypoglycemia episodes were higher during the BP arm than the UC arm (0.7 vs. 0.4 median episodes per day, P = 0.01). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Adults with CFRD had improved glucose control without an increase in CGM-measured hypoglycemia with the BP compared with their UC, suggesting that this may be an important therapeutic option for this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-1411","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T16:51:01Z","timestamp":1698166261000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":23,"title":["Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis\u2013 Related Diabetes"],"prefix":"10.2337","volume":"47","author":[{"given":"Jordan S.","family":"Sherwood","sequence":"first","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz E.","family":"Castellanos","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie Y.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Balliro","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"},{"name":"2Beta Bionics Inc., Concord, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory A.","family":"Hillard","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"},{"name":"2Beta Bionics Inc., Concord, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Grace","family":"Gaston","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bartholomew","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Greaux","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sabean","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[{"name":"3Biostatics Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Marchetti","sequence":"additional","affiliation":[{"name":"4Division of Pulmonary Medicine, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Uluer","sequence":"additional","affiliation":[{"name":"4Division of Pulmonary Medicine, Boston Children\u2019s Hospital, Boston, MA"},{"name":"5Division of Pulmonology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[{"name":"4Division of Pulmonary Medicine, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Neuringer","sequence":"additional","affiliation":[{"name":"6Division of Pulmonology and Critical Care, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas H.","family":"El-Khatib","sequence":"additional","affiliation":[{"name":"2Beta Bionics Inc., Concord, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Damiano","sequence":"additional","affiliation":[{"name":"2Beta Bionics Inc., Concord, MA"},{"name":"7Department of Biomedical Engineering, Boston University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Russell","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"},{"name":"2Beta Bionics Inc., Concord, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-8954","authenticated-orcid":false,"given":"Melissa S.","family":"Putman","sequence":"additional","affiliation":[{"name":"1Diabetes Research Center, Massachusetts General Hospital, Boston, MA"},{"name":"8Department of Endocrinology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2023122019552474200_B1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2023122019552474200_B2","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2023122019552474200_B3","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"2023122019552474200_B4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000110206","article-title":"Long-term effect of insulin treatment in cystic fibrosis-related diabetes","volume":"76","author":"Mohan","year":"2008","journal-title":"Respiration"},{"key":"2023122019552474200_B5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr"},{"key":"2023122019552474200_B6","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2023122019552474200_B7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2023122019552474200_B8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2337\/dc21-0172","article-title":"Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes","volume":"44","author":"Brown","year":"2021","journal-title":"Diabetes Care"},{"key":"2023122019552474200_B9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"key":"2023122019552474200_B10","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2589-7500(22)00020-6","article-title":"Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial","volume":"4","author":"Ware","year":"2022","journal-title":"Lancet Digit Health"},{"key":"2023122019552474200_B11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/dia.2021.0097","article-title":"one year real-world use of the Control-IQ advanced hybrid closed-loop technology","volume":"23","author":"Breton","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa2004736","article-title":"A randomized trial of closed-loop control in children with type 1 diabetes","volume":"383","author":"Breton","year":"2020","journal-title":"N Engl J Med"},{"key":"2023122019552474200_B13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","article-title":"Multicenter, randomized trial of a bionic pancreas in type 1 diabetes","volume":"387","author":"Russell","year":"2022","journal-title":"N Engl J Med"},{"key":"2023122019552474200_B14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/dia.2021.0354","article-title":"The effect of Control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes","volume":"24","author":"Scully","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jcf.2019.08.002","article-title":"Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: a pilot study","volume":"19","author":"Sherwood","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2023122019552474200_B16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/dia.2022.0167","article-title":"A multicenter randomized trial evaluating fast-acting insulin aspart in the bionic pancreas in adults with type 1 diabetes","volume":"24","author":"Beck","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/dia.2022.0341","article-title":"The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: a multi-center single-arm evaluation of the insulin-only configuration of the bionic pancreas in adults and youth with type 1 diabetes","volume":"24","author":"Lynch","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/dia.2022.0200","article-title":"A multicenter randomized trial evaluating the insulin-only configuration of the bionic pancreas in adults with type 1 diabetes","volume":"24","author":"Kruger","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/dia.2022.0201.pub","article-title":"Positive impact of the bionic pancreas on diabetes control in youth 6-17 years old with type 1 diabetes: a multicenter randomized trial","volume":"24","author":"Messer","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(16)32567-3","article-title":"Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial","volume":"389","author":"El-Khatib","year":"2017","journal-title":"Lancet"},{"key":"2023122019552474200_B21","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1210\/jc.2013-4151","article-title":"Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes","volume":"99","author":"El-Khatib","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2023122019552474200_B22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1056\/NEJMoa1314474","article-title":"Outpatient glycemic control with a bionic pancreas in type 1 diabetes","volume":"371","author":"Russell","year":"2014","journal-title":"N Engl J Med"},{"key":"2023122019552474200_B23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2213-8587(15)00489-1","article-title":"Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial","volume":"4","author":"Russell","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023122019552474200_B24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/dia.2010.0199","article-title":"Using a multi-level B-spline model to analyze and compare patient glucose profiles based on continuous monitoring data","volume":"13","author":"Zheng","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"2023122019552474200_B25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2023122019552474200_B26"},{"key":"2023122019552474200_B27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcf.2008.12.001","article-title":"Use of the insulin pump in treat cystic fibrosis related diabetes","volume":"8","author":"Hardin","year":"2009","journal-title":"J Cyst Fibros"},{"key":"2023122019552474200_B28","first-page":"100267","article-title":"Spontaneous and iatrogenic hypoglycemia in cystic fibrosis","volume":"26","author":"Hicks","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2023122019552474200_B29","first-page":"100","article-title":"Patient and parent perceptions of the diagnosis and management of\u00a0cystic fibrosis-related diabetes","volume":"1","author":"Millington","year":"2014","journal-title":"J Clin Transl Endocrinol"},{"key":"2023122019552474200_B30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jcf.2019.03.007","article-title":"The impact of cystic fibrosis-related diabetes on health-related quality of life","volume":"18","author":"Kwong","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2023122019552474200_B31","first-page":"753","article-title":"Perceptions of diabetes technology use in cystic fibrosis-related diabetes management","volume":"23","author":"Marks","year":"2021","journal-title":"Diabetes Technol Ther"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/1\/101\/741582\/dc231411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/1\/101\/741582\/dc231411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T14:56:52Z","timestamp":1703084212000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/1\/101\/153790\/Randomized-Trial-of-the-Insulin-Only-iLet-Bionic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,24]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1411","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}